Dress, it looks like the drug failed because of the adverse side effects in 80% of patients. Brother we didn't get to skip Phase 2 for no reason at all. Anyone selling because of another companies bad news could miss out. There isn't many companies in the Phase 3 trials. I think we are still okay here.
Market Data 
Markets 
AI
